COLUMBUS, Ohio--(BUSINESS WIRE)--Phylogeny, Inc., the in situ company, and Neoprobe have been awarded a $1M grant from the Ohio Third Frontier program. The grant will help accelerate the phase III clinical trial of Neoprobe’s radiopharmaceutical, Lymphoseek.
